Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer

By sjmartinez • September 28, 2023

Zhao JJ, Fong KY, Chan YH, Tey J, Dawood S, Lee SC, Finn RS, Sundar R, Lim JSJ. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer. Cancers (Basel). 2023 Sep 14;15(18):4558. doi: 10.3390/cancers15184558. PMID: 37760527.

Tags: CDK4/6-inhibitor, Hematology/Oncology, metastatic breast cancer, Publications

Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

Shibata T, Bhat S, Cao D, Saito S, Khan N, Bernstein EA, Tokudome T, Okwan-Duodu D, Tourtellotte WG, Bernstein KE, Khan Z. Bioengineered iPSC-derived human[...]

First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Stud

Gray JE, Neal JW, Patel JD, Liu SV, Veillon R, Reck M, Cappuzzo F, Cobo M, Reguart N, Fuentes Pradera J, Cho BC, Mok T,[...]

Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape

Hennessy MA, Terman E, Idossa D, LeVee A, Leon-Ferre RA, McArthur H, Nanda R. Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.[...]